Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 3/20 | 0.73 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.68 |
| ▸ | CA1 | P00915 | 1/20 | 0.68 |
| ▸ | CA2 | P00918 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.67 |
| ▸ | MEN1 | O00255 | 3/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | PGR | P06401 | 1/20 | 0.59 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28271812 | 0.85 | HTR6 (1.00) | HTR6CYP19A1CA1CA2KMT2A | |
| SCHEMBL3841821 | 0.85 | PRMT1 (0.66) | HTR6CYP19A1CA1CA2KMT2A | |
| SCHEMBL3791521 | 0.85 | PGR (0.81) | HTR6CYP19A1KMT2AMEN1ALOX15 | |
| SCHEMBL28121847 | 0.84 | PGR (0.73) | PRMT1PKMPGRKEAP1 | |
| SCHEMBL14937571 | 0.84 | PGR (0.72) | CYP19A1CA1CA2KMT2AMEN1 | |
| SCHEMBL28271815 | 0.84 | HTR6 (0.79) | HTR6CYP19A1CA1CA2KMT2A | |
| SCHEMBL30737524 | 0.84 | HTR6 (0.79) | HTR6CYP19A1CA1CA2KMT2A | |
| SCHEMBL30737484 | 0.83 | PGR (0.71) | HTR6CYP19A1KMT2AMEN1ALDH1A1 | |
| SCHEMBL29561272 | 0.83 | PGR (0.67) | CYP19A1KMT2AMEN1ALOX15ALDH1A1 | |
| SCHEMBL16431575 | 0.83 | PGR (0.71) | HTR6CYP19A1KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11236044-B2 | Selective inhibitors of 12(S)-lipoxygenase (12-LOX) and methods for use of the same | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-02-01 | — | — | US | disclosed |
| US-20210147348-A1 | SELECTIVE INHIBITORS OF 12(S)- LIPOXYGENASE (12-LOX) AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-05-20 | — | — | US | disclosed |
| CN-112566898-A | Selective inhibitors of 12(S) -lipoxygenase (12-LOX) and methods of use thereof | 密歇根大学董事会 | 2021-03-26 | — | — | CN | disclosed |
| EP-3781548-A1 | SELECTIVE INHIBITORS OF 12(S)-LIPOXYGENASE (12-LOX) AND METHODS FOR USE OF THE SAME | The Regents Of The University Of Michigan (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2019204375-A1 | SELECTIVE INHIBITORS OF 12(S)-LIPOXYGENASE (12-LOX) AND METHODS FOR USE OF THE SAME | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-10-24 | — | — | WO | disclosed |
| US-8637529-B2 | Pyrazolo[3,4-d]pyrimidine compounds | AbbYie Inc. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2012-01-19 | — | — | US | disclosed |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| EP-1353922-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | Cancer Research Technology Limited (GB) | 2003-10-22 | — | — | EP | disclosed |
| WO-2002059125-A1 | CYCLIN DEPENDENT KINASE INHIBITING PURINE DERIVATIVES | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015963-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS | CHUK, MAP2K2, CDK3 | HTR6 2181/4885CYP19A1 1570/4885CA1 4398/4885 |
| US-11236044-B2 | Selective inhibitors of 12(S)-lipoxygenase (12-LOX) and methods for use of the same | ALOX12, LOX, ALOX15 | HTR6 1167/4885CYP19A1 337/4885CA1 4625/4885 |
| US-20210147348-A1 | SELECTIVE INHIBITORS OF 12(S)- LIPOXYGENASE (12-LOX) AND METHODS FOR USE OF THE SAME | ALOX12, LOX, ALOX15 | HTR6 1167/4885CYP19A1 337/4885CA1 4625/4885 |
| US-20040110775-A1 | Cyclin dependent kinase inhibiting purine derivatives | CCNA1, CDKL1, CCNK | HTR6 1629/4885CYP19A1 1006/4885CA1 2976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.